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Abstract
Background: Mammalian circadian clocks control multiple physiological events. The principal
circadian clock generates seasonal variations in behavior as well. Seasonality elevates the risk for
metabolic syndrome, and evidence suggests that disruption of the clockwork can lead to alterations
in metabolism. Our aim was to analyze whether circadian clock polymorphisms contribute to
seasonal variations in behavior and to the metabolic syndrome.
Methods: We genotyped 39 single-nucleotide polymorphisms (SNP) from 19 genes which were
either canonical circadian clock genes or genes related to the circadian clockwork from 517
individuals drawn from a nationwide population-based sample. Associations between these SNPs
and seasonality, metabolic syndrome and its risk factors were analyzed using regression analysis.
The p-values were corrected for multiple testing.
Results: Our findings link circadian gene variants to the risk factors of the metabolic syndrome,
since Npas2 was associated with hypertension (P-value corrected for multiple testing = 0.0024) and
Per2 was associated with high fasting blood glucose (P-value corrected for multiple testing = 0.049).
Conclusion: Our findings support the view that relevant relationships between circadian clocks
and the metabolic syndrome in humans exist.
Background
Circadian clocks regulate the timing of biological events
including the sleep-wake cycle, energy metabolism, and
secretion of hormones. The principal clock conducting
the circadian system is located in the suprachiasmatic
nuclei of the anterior hypothalamus. From the brain,
information is sent out to regulate and reset the peripheral
clocks [1]. Seasonal variations in behavior are generated
by the principal clock as well [2]. Light exposures stimu-
late the principal clock through pathways from the retina,
and the most important cues for reset of the principal cir-
cadian clock are the light-dark transitions, while the
peripheral clocks are set by metabolic signals in response
to feeding cycles [3]. With shortage of daylight, the meta-
bolic cycles may take over and serve as the standard for the
circadian clockwork [4]. In hibernating mammals, the
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metabolic futile cycle can provide the animal with those
circadian signals needed for reset [5]. When there exists no
light-dark transitions to reset the principal clock, reindeer
living above the Arctic Circle use the metabolic cycles as
the reference instead [6].
The molecular circadian clock consists of multiple posi-
tive and negative feedback loops that generate the 24-
hour oscillation of target genes. In the positive loop
NPAS2 (MOP4) protein [7], which plays an overlapping
role with the CLOCK protein [8], pairs up with ARNTL
(BMAL1 or MOP3) protein. These heterodimers activate
the transcription of target genes (for review, see [9]).
Downstream, PER and CRY proteins pair up and execute
the negative loop. Nuclear receptor co-activators and
repressors and several post-transcriptional modifications
are necessary for clock precision. In addition, clockwork
output molecules can provide an input to the following
cycles [10].
Circadian clocks and energy metabolism are linked
because the disruptions of the clockwork lead to altera-
tions in metabolism and vice versa (for review, see [11]).
Mutation in the Clock gene leads to metabolic syndrome
in mice [12], and in humans Clock polymorphisms have
been associated with obesity and metabolic syndrome
[13,14]. Cellular metabolic states can serve as a link
between stimuli from the habitat and drive for the clock-
work, because the reduced forms of nicotinamide adenine
dinucleotide cofactors stimulate DNA binding of the
NPAS2-ARNTL [15] and CLOCK-ARNTL [16] heterodim-
ers, whereas the oxidized forms inhibit the binding [17].
Npas2-deficient mice have reduced ability to adapt to
restricted feeding [18], whereas Clock-deficient mice adapt
to it even better than do wild-type mice [19], suggesting a
key role of NPAS2.
Herein, we hypothesized that circadian clock polymor-
phisms contribute to the routine seasonal variations and
to the metabolic syndrome. Our earlier finding that sea-
sonality was associated with the metabolic syndrome
[20], gave a rationale for the current study.
Methods
This study was part of a nationwide health interview and
examination survey, the Health 2000 Study, which was
carried out in Finland, a north-eastern (60–70°N, 20–
31°E) European country with about 5 million inhabit-
ants, from September 2000 to June 2001. The two-stage
stratified cluster sampling design was planned by Statistics
Finland. The sampling frame comprised adults living in
mainland Finland. This frame was regionally stratified
according to the five university hospital regions, or catch-
ments areas, each containing roughly one million inhab-
itants. From each university hospital region, 16 health
care districts were sampled as clusters (80 health care dis-
tricts in the whole country, including 160 municipalities,
or groups of municipalities with joint primary care). The
15 biggest health care districts in the country were all
selected in the sample and their sample sizes were propor-
tional to population size. The remaining 65 health care
districts were selected by systematic probability propor-
tional to size sampling in each stratum, and their sample
sizes (ranging from 50 to 100) were equal within each
university hospital region, the total number of persons
drawn from a university hospital region being propor-
tional to the corresponding population size. The 80
health care districts were the primary sampling units, and
the ultimate sampling units were persons who were
selected by systematic sampling from the health centre
districts. From these 80 health care districts, a random
sample of individuals was drawn using the data provided
by Population Register Centre. Its population information
system contains the official information for the whole
country on the Finnish citizens and aliens residing perma-
nently in Finland. All the persons aged 30 and over (n =
8028) who were identified from the nationally represent-
ative sample by The Social Insurance Institution of Fin-
land were contacted in person. Interviewers attended
training sessions on the specific themes that were to be
covered in the computer-assisted interviews. Of the final
sample of 7979 persons, 6986 (88%) were interviewed at
home or institution face to face and 6354 (80%) attended
the health status examination in a local health center or
equal setting, while 416 took part in the health status
examination at home or in an institution. Overall, 84%
participated either in the health status examination
proper or in the examination at home. All the methods are
reported in more detail on the Internet site of the Health
2000 http://www.ktl.fi/health2000.
Phenotype data
All participants had been asked to come to the health sta-
tus examination fasting at least 4 hours and without
drinking on the same day. In the laboratory, a nurse
recorded how these instructions had been followed and
then took the blood samples. The samples were centri-
fuged at the examination site and placed into deep freez-
ers at -20°C before they were transferred within one week
to the National Public Health Institute and stored in deep
freezers at -70°C. Routine fasting laboratory tests
included the concentrations of blood glucose and those of
serum total cholesterol and triglycerides (Glucose Hexoki-
nase, Cholesterol CHOD PAP and Triglycerides GPO PAP,
Olympus System Reagent, Germany), those of HDL cho-
lesterol and low-density lipoprotein (LDL) cholesterol
(HDL-C Plus and LDL-C Plus, Roche Diagnostics GmbH,
Germany), and those of gamma-glutamyltransferase
(GGT) and uric acid (IFCC/ECCLS and URIKAASI PAP,
Konelab, Thermo Electron Oy, Finland).Journal of Circadian Rhythms 2009, 7:5 http://www.jcircadianrhythms.com/content/7/1/5
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The diagnostic mental health interview was performed at
the end of the comprehensive health examination. The
computerized version of the CIDI (M-CIDI) was used. The
program uses algorithms to meet the Diagnostic and Sta-
tistical Manual of Mental Disorders (DSM-IV) criteria and
allows the estimation of DSM-IV diagnoses for major dis-
orders [21]. The translation of the M-CIDI into Finnish
was made pair wise by psychiatric professionals and
revised by others. The official Finnish translation of the
DSM-IV classification was used as a basis for formulating
the interview. The process included consensus meetings,
third expert opinions, an authorized translator's review,
and testing with both informed test subjects and unse-
lected real subjects [22]. Interviews were performed to
determine the 12-month prevalence rates of major depres-
sive episodes and disorder, dysthymia, general anxiety dis-
order, panic disorder with or without agoraphobia, social
phobia, alcohol abuse and dependence, and other sub-
stance dependence and abuse.
As part of the assessment, the participants filled in the
items of lifetime seasonal variations in mood and behav-
ior taken and adapted from the Seasonal Pattern Assess-
ment Questionnaire (SPAQ) [23]. The questionnaire was
translated into Finnish and then back-translated to revise
the linguistic accuracy. Each of the six items of sleep
length, social activity, mood, weight, appetite, and energy
level was scored from 0 to 3 (none, slight, moderate or
marked change), not from 0 to 4 (none, slight, moderate,
marked or extremely marked change), with the sum or
global seasonality score (GSS) ranging from 0 to 18. A
dichotomous variable depicting seasonality was derived
from the distribution of global scores on the modified
questionnaire and based on the provisional criteria simi-
lar to the original ones [24], the GSS ranging from 0–7
(not affected) and 8–18 points (affected).
There are several definitions for metabolic syndrome and
its risk factors. In this study we used US Adult Treatment
Panel III of the National Cholesterol Education Program
(NCEP-ATPIII) criteria [NCEP 2002] and the Interna-
tional Diabetes Federations (IDF) criteria [IDF 2005] to
determine metabolic syndrome.
The US Adult Treatment Panel III of the National Choles-
terol Education Program (NCEP-ATPIII) criteria for meta-
bolic syndrome is [NCEP 2002] defined as having at least
three of the following components: the fasting blood glu-
cose level 6.1 mmol/l or higher, the high blood pressure
(systolic pressure 130 mmHg or more or diastolic pressure
85 mmHg or more), the serum triglycerides level 1.7
mmol/l or higher, the serum high-density lipoprotein
cholesterol level lower than 1.0 mmol/l for men or lower
than 1.3 mmol/l for women, or the waistline 102.1 cm or
more for men or 88.1 cm or more for women.
The International Diabetes Federations (IDF) criteria for
metabolic syndrome [IDF 2005] is defined as having
waistline of 94 cm or more for men or 80 cm or more for
women and at least two of the following components: the
serum triglycerides level 1.7 mmol/l or higher, the serum
high-density lipoprotein cholesterol level lower than 1.02
mmol/l for men or lower than 1.29 mmol/l for women,
high blood pressure in terms of systolic pressure 130
mmHg or more or diastolic pressure 85 mmHg or more or
treatment for previously diagnosed hypertension and
raised fasting plasma glucose level 5.6 mmol/l or higher,
or previously diagnosed type 2 diabetes.
The individual risk factor variables are listed below. These
include the variables forming the criteria's above and in
addition supplemental variables, that World Health
Organization (WHO) and European Group for the Study
of Insulin Resistance (EGIR) consider as risk factors for
metabolic syndrome and American Association of Clini-
cal Endocrinologists (AACE) use to define Insulin Resist-
ance Syndrome.
The blood pressure was defined high when mean value of
systolic blood pressure was 140 mmHg or more or diasto-
lic blood pressure was 90 mmHg or more. A variable tak-
ing into account high blood pressure and in addition a
treatment for previously diagnosed hypertension was cre-
ated. We also used a variable which defined blood pres-
sure high when mean value of systolic blood pressure was
130 mmHg or more or diastolic blood pressure was 85
mmHg or more. A variable with preceding and hyperten-
sion medication was also included in the study.
The serum high-density lipoprotein (HDL) cholesterol
level was considered low when it was lower than 1.02
mmol/l for men or lower than 1.29 mmol/l for women.
We also used another variable with thresholds of 1.0
mmol/l and 1.3 mmol/l, respectively. The triglyceride lev-
els were considered raised if they were higher than 1.7
mmol/l in both genders. A variable taking into account
raised triglyceride levels and also the low HDL cholesterol
in terms of 0.9 mmol/l or less in men and 1.0 mmol/l in
women was used. A variable with triglycerides termed
high when higher than 2 mmol/l or HDL was less than 1.0
mmol/l or person was using lipid medication was also
used in this study.
Plasma glucose levels were measured after fasting at least
for 4 hours. The first variable considered fasting plasma
glucose levels raised if they were 6.1 mmol/l or higher.
The second variable was positive if the fasting glucose lev-
els were between 6.1–6.9 mmol/l. The third variable was
positive if fasting plasma glucose levels were 5.6 mmol/l
or higher, or the individual had previously diagnosed type
2 diabetes.Journal of Circadian Rhythms 2009, 7:5 http://www.jcircadianrhythms.com/content/7/1/5
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Waist circumference was measured in centimeters. We
also used two additional variables to define the waistline
status: In the first variable circumference was considered
high when it was 102 cm or more for men or 88 cm or
more for women, in the second variable the values were
94 cm or more for men or 80 cm or more for women. The
waist/hips circumference ratio was determined high when
it was 0.9 or more for men or 0.85 or more for women.
Study sample
Overall, the 5480 individuals participated in the health
status examination and the diagnostic mental health
interview, filled in the self-report of seasonal changes in
mood and behavior and gave venous blood samples for
DNA extraction and were screened with the M-CIDI inter-
view to have no mental illness according to the DSM-IV
criteria. Among these individuals, 517 were randomly
selected to form the final study sample.
Gene and SNP selection
A total of 39 single-nucleotide polymorphisms (SNPs) of
19 genes were genotyped (Table 1). Herein, we wanted to
focus on the circadian clock and selected genes which
were either canonical circadian clock genes (Arntl, Arntl2,
Clock, Cry2, Npas2, Per2 and Timeless) or genes having
their influence on pathways related to the circadian clock-
work (Adcyap1, Drd2, Opn4, Npy, Vip, Vipr2, Fdft1). Since
the circadian clockwork and sleep are interactive, specific
sleep-related genes were included (Acads, Ada and Glo1).
Arntl2 was included in the study because it has significant
homology with Arntl1 and Ncoa because it has significant
sequence homology with Clock and therefore a possible
role in the circadian clock [25,26]. Both candidate SNPs
and tag-SNPs were included in this study. Candidate SNPs
were selected based on their possible functional potential
including variation resulting in amino acid change (i.e.
missense, Table 1) and SNPs previously reported to have
relevance to seasonal changes in mood and behavior.
HapMap tag-SNPs were selected in order to improve the
coverage.
Genotype analysis
Genomic DNA was isolated from the whole blood accord-
ing to standard procedures. SNPs were genotyped with a
fluorogenic 5' nuclease assay method (TaqMan™) with
pre-designed primer-probe kits (TaqMan® Pre-Designed
SNP Genotyping Assays) using the Applied Biosystems
7300 Real Time PCR System (Applied Biosystems, Foster
City, California, USA) according to the instructions pro-
vided by the manufacturer.
Custom TaqMan® SNP Genotyping Assays were used for
three SNPs. The primere sequences were CGCACGAG-
GGCACCAT and TGGGCCCCGCTAAGC and the reporter
sequences ACTTTGGGCTTGTCGAA and ACTTTGGGCTT-
GTTGAA for ADA 22G>A (Asp8Asn), AAGCCGACTTTGC
CTGAGT and ACAAGGAGCCGGGTTCTG and the reporter
sequences CTTGGGCATTTTCAT and TTGG GC GTTTTCAT
for PER2 10870, and GCTCAGCAGCAGCCT GAA and
CGAAACTGCGACTGGTCTGATT and the reporter
sequences CTTGCTACAAGTATCTC and TTGCTACAGG-
TATCTC for FDFT1 rs11549147.
All samples were successfully genotyped, yielding the suc-
cess rate of 100% for all SNPs, and about 5% of samples
were re-genotyped to confirm the genotyping results. The
following three SNPs were not in the Hardy-Weinberg
equilibrium: ARNTL rs1982350 (P = 0.01), ARNTL
rs6486120 (P = 0.009) and PER2 rs934945 (P = 0.05).
Statistical analysis
Genotype frequencies, allele frequencies and Hardy-
Weinberg p-values were calculated with the Pearson exact
test. Only those haplotypes occurring with a frequency
>0.05 were considered. The linkage disequilibrium (LD)
between the SNPs analyzed was estimated. The remaining
35 SNPs were tested using additive model. Coefficients,
odds ratios (OR) and their 95% confidence intervals (CI)
were calculated. The sex and age were controlled for these
analyses. The p-values were corrected to reduce the false
positives resulting from multiple testing by using an
approximation of Bonferroni-p-values: we selected associ-
ations with significant p-values and low false discovery
rates (FDR below 0.05) and then corrected the p-values
with the number of the genes analyzed (17). Statistical
analysis was performed using the R software, version 2.5.0
[27], and the PLINK software, version v1.04 [28].
Ethics
The study project was coordinated by the National Public
Health Institute and implemented in collaboration with
social insurance organizations and the Ministry of Social
Affairs and Health. It provided a written informed consent
to each participant, giving a full description of the proto-
col before signing it. The procedures were according to the
ethical standards of the responsible committee on human
experimentation and with the Declaration of Helsinki, its
amendments and revision.
Results
The allele frequencies and genotype distributions of the
SNPs are shown in Table 1. The first 100 samples geno-
typed indicated that in our Finnish study population four
SNPs were not polymorphic, including Arntl2
rs35878285, Cry2 rs2863712, Ncoa3 rs2230783 and Per2
S662G, so these were excluded from further analysis. Each
polymorphic SNP was then analyzed in relation to sea-
sonality and to metabolic syndrome risk factors. The sig-
nificant results are presented in Table 2.Journal of Circadian Rhythms 2009, 7:5 http://www.jcircadianrhythms.com/content/7/1/5
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Table 1: Genotypes and allele frequencies.
Gene SNPa Mutation Type Allele 1b Allele 2 n 1 (freq)C n 2 (freq) n 11 (freq) n12 (freq) n 22 (freq)
Acads rs1799958 missense G A 768 (0.74) 266 (0.26) 283 (0.55) 202 (0.39) 32 (0.06)
Ada 22G>A missense G A 978 (0.95) 56 (0.05) 461 (0.89) 56 (0.11) 0
Adcyap1 rs2856966 missense A G 850 (0.82) 184 (0.18) 344 (0.67) 162 (0.31) 11 (0.02)
Arntl rs6486120 intronic G T 744 (0.72) 290 (0.28) 280 (0.54) 184 (0.36) 53 (0.10)
rs1982350 intronic G A 587 (0.57) 447 (0.43) 181 (0.35) 225 (0.44) 111 (0.21)
rs3816360 intronic C T 552 (0.53) 482 (0.47) 152 (0.29) 248 (0.48) 117 (0.23)
rs2278749 intronic C T 823 (0.80) 211 (0.20) 328 (0.63) 167 (0.32) 22 (0.04)
rs2290035 intronic A T 595 (0.58) 439 (0.42) 175 (0.34) 245 (0.47) 97 (0.19)
Arntl2 rs7958822 intronic G A 560 (0.54) 474 (0.46) 147 (0.28) 266 (0.51) 104 (0.20)
rs4964057 intronic T G 601 (0.58) 433 (0.42) 178 (0.34) 245 (0.47) 94 (0.18)
rs1037921 missense A G 947 (0.92) 87 (0.08) 433 (0.84) 81 (0.16) 3 (0.01)
rs2306074 intronic T C 668 (0.65) 366 (0.35) 213 (0.41) 242 (0.47) 62 (0.12)
rs35878285 mis-sense A 1034 (1.00) 517(1.00)
Clock rs2412646 intronic C T 760 (0.74) 274 (0.26) 280 (0.54) 200 (0.39) 37 (0.07)
rs11240 intronic C G 696 (0.67) 338 (0.33) 227 (0.44) 242 (0.47) 48 (0.09)
rs2412648 intronic T G 654 (0.63) 380 (0.37) 210 (0.41) 234 (0.45) 73 (0.14)
rs3805151 intronic T C 613 (0.59) 421 (0.41) 183 (0.35) 247 (0.48) 87 (0.17)
Cry2 rs2863712 missense T 1034 (1.00) 517(1.00)
Drd2 rs1800497 missense G A 838 (0.81) 196 (0.19) 336 (0.65) 166 (0.32) 15 (0.03)
rs6277 silent G A 542 (0.52) 492 (0.48) 141 (0.27) 260 (0.50) 116 (0.22)
Fdft1 rs11549147 missense A G 944 (0.91) 90 (0.09) 431 (0.83) 82 (0.16) 4 (0.01)
Glo1 rs2736654 missense T G 662 (0.64) 372 (0.36) 207 (0.40) 248 (0.48) 62 (0.12)
Opn4 rs1079610 missense T C 714 (0.69) 320 (0.31) 246 (0.48) 222 (0.43) 49 (0.09)
Ncoa3 rs6094752 missense C T 1003 (0.97) 31 (0.03) 486 (0.94) 31 (0.06) 0
rs2230782 missense G C 932 (0.9) 102 (0.1) 422 (0.82) 88 (0.17) 7 (0.01)
rs2230783 missense T 1034 (1.00) 517(1.00)
Npas2 rs11541353 missense C T 859 (0.83) 175 (0.17) 358 (0.69) 143 (0.28) 16 (0.03)
rs2305160 missense G A 727 (0.7) 307 (0.3) 252 (0.49) 223 (0.43) 42 (0.08)Journal of Circadian Rhythms 2009, 7:5 http://www.jcircadianrhythms.com/content/7/1/5
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We found associations with circadian clock genes and the
risk factors for metabolic syndrome. Npas rs11541353
was associated with hypertension, the minor allele being
protective against hypertension (T vs. C, OR = 0.54, Cor-
rected P-value = 0.02). The results almost the same when
people getting treatment for their hypertension were
included in group (T vs. C, OR = 0.53, Corrected P-value
= 0.015). Per2 10870 was associated with glucose metab-
olism. 10870 minor allele reduced the risk of raised
plasma glucose (G vs. A, Beta coefficient = -0.010, Cor-
rected P-value = 0.049).
Discussion
Our main results herein are that Npas2 is linked to hyper-
tension and that Per2 is associated with blood glucose lev-
els.
Npy rs16139 missense T C 956 (0.92) 78 (0.08) 444 (0.86) 68 (0.13) 5 (0.01)
Per2 rs934945 missense C T 917 (0.89) 117 (0.11) 402 (0.78) 113 (0.22) 2 (0.004)
10870 intronic A G 854 (0.83) 180 (0.17) 350 (0.68) 154 (0.30) 13 (0.03)
rs2304672 UTR 5' G C 865 (0.84) 169 (0.16) 361 (0.70) 143 (0.28) 13 (0.03)
S662G missense T 1034 (1.00) 517(1.00)
Plcb4 rs6077510 missense A G 552 (0.53) 482 (0.47) 142 (0.27) 268 (0.52) 107 (0.21)
Timeless rs2291739 missense A G 624 (0.6) 410 (0.4) 193 (0.37) 238 (0.46) 86 (0.17)
rs2291738 intronic C T 546 (0.53) 488 (0.47) 147 (0.28) 252 (0.49) 118 (0.23)
Vip rs3823082 intronic C T 854 (0.83) 180 (0.17) 351 (0.68) 152 (0.29) 14 (0.03)
rs688136 UTR 3' T C 676 (0.65) 358 (0.35) 221 (0.43) 234 (0.45) 62 (0.12)
Vipr2 rs885863 UTR 3' T C 518 (0.50) 516 (0.50) 126 (0.24) 266 (0.51) 125 (0.24)
a) dbSNP symbols http://www.ncbi.nlm.nih.gov/SNP
b) Alleles extracted from HapMap http://www.HapMap.org
c) Total number of alleles in study sample, frequencies in parenthesis.
Table 1: Genotypes and allele frequencies. (Continued)
Table 2: Results from one-SNP analysis.
Variable Gene SNP P-value P-value corrected for multiple testing Beta-coefficient 95% CI
Fasting blood glucose level (Logarithmic) a Per2 #10870 0.002 0.049 -0.010 -0.016–-0.035
Variable Gene SNP P-value P-value corrected for multiple testing Odds ratio 95% CI
High blood pressure b Npas2 rs11541353 0.001 0.02 0.54 0.37–0.79
High blood pressure or hypertension 
medication c
Npas2 rs11541353 <0.001 0.015 0.53 0.36–0.77
Single SNPs were analyzed using linear regression for continuous variables and logistic regression for dichotomous variables. Betacoefficients were 
calculated for continuous variables, odds ratios for dichotomous variables. The sex and age were controlled for these analyses. P-values corrected 
for multiple testing were calculated.
a) The concentrations of blood glucose (mmol/L) after fasting at least 4 hours and without drinking on the same day. The variable was log-
transformed to obtain the normal distribution.
b) The blood pressure was defined high when systolic pressure was 140 mmHg or higher or diastolic pressure was 90 mmHg or higher.
c) High blood pressure (b) or treatment for previously diagnosed hypertension.Journal of Circadian Rhythms 2009, 7:5 http://www.jcircadianrhythms.com/content/7/1/5
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Seasonality and disruption of circadian molecular clock-
work are risk factors for metabolic syndrome ([12,20]. We
now found that the common risk factors for metabolic
syndrome are associated with polymorphisms in circa-
dian clock genes. Npas2 rs11541353 was associated with
hypertension in the Finnish population. Earlier, Arntl was
linked to hypertension and type 2 diabetes mellitus [29].
Now, we demonstrate herein the associations of Npas2
with hypertension and of Per2 with blood glucose levels.
Together these earlier findings and those of ours empha-
size the importance of the circadian system and its core
genes in regulation of blood pressure, and point to a role
in pathological situations. Moreover, they parallel to SAD
in which there is a strong metabolic component and with
which this unit of ARNTL, NPAS2 and PER2 is associated
[30]. There are often not only disturbances in the meta-
bolic networks [31] but also disruptions of the circadian
rhythms [32] together with pronounced seasonal changes
in mood and behavior [33] in individuals having affective
disorders. Now, this may concern the general population
as well.
Npas2 rs11541353 is a missense mutation, leading to
substitution of serine with leusine in the amino acid posi-
tion 471. Npas2 rs11541353 minor allele was protective
against hypertension and heterozygosity of Npas2
rs11541353 is protective against Seasonal affective disor-
der (SAD) [30]. These findings reveal that protection from
seasonal variations and protection from high blood pres-
sure go hand in hand in some cases. However, Partonen et
al. also found that homozygosity for both Npas2
rs11541353 minor and major alleles was a major risk fac-
tor for SAD. Combining these results, persons with two
major alleles of Npas2  rs11541353 have substantially
increased risk not only for SAD but also for hypertension.
However, when a person has two Npas2  rs11541353
minor alleles, the results are difficult to interpret, as the
homozygosity increases the odds for SAD, but protects
against hypertension. Next, the phenotypes in terms of
SAD and hypertension in Npas2 rs11541353 homozygous
and heterozygous persons need to be analyzed.
Our results indicate, that Per2  10870 contributed to
changes in glucose metabolism. Per2 10870 is an intronic
mutation originally found by Spanagel et al (2005), when
searching for the Per2 SNPs modulating alcohol intake in
mice. Its minor allele G was protective against high alco-
hol intake in humans [34] but increased the odds for SAD
[30]. In our current study, the minor allele G reduced the
risk for raised plasma glucose levels. Lamia et al. previ-
ously demonstrated that Per1-/-;Per2-/- mice have altered
blood glucose homeostasis [35]. Another recent study
demonstrated that administration of metformin, one of
the most commonly used drugs for type 2 diabetes, leads
to the degradation of PER2 and to a phase advance in the
Table 3: Single SNP analysis with corrected p- values = 0.10.
Variable Gene SNP P-value P-value corrected for multiple testing Beta- coefficient 95% CI
Fasting blood glucose level (Logarithmic) a DRD2 rs6277 0.003 0.051 -0.008 -0.012–-0.003
Waist circumference b PLCB4 rs6077510 0.004 0.085 2.0 0.63–3.4
Variable Gene SNP P-value P-value corrected for multiple testing Odds ratio 95% CI
High waist circumference c Per2 rs934945 0.003 0.062 1.9 1.2–3.0
Low HDL cholesterol d Vipr2 rs885863 0.004 0.069 1.5 1.1–2.0
Metabolic syndrome [IDF] f Per2 rs934945 0.004 0.070 1.9 1.2–2.9
Single SNPs were analyzed using linear regression for continuous variables and logistic regression for dichotomous variables. Betacoefficients were calculated 
for continuous variables, odds ratios for dichotomous variables. The sex and age were controlled for these analyses. P-values corrected for multiple testing 
were calculated.
a) The concentrations of blood glucose (mmol/L) after fasting at least 4 hours and without drinking on the same day. The variable was log-transformed to 
obtain the normal distribution.
b) Waist circumference in centimeters
c) Waist circumference 94 cm or more for men or 80 cm or more for women
d) Serum high-density lipoprotein (HDL) cholesterol level was considered low when it was lower than 1.02 mmol/l for men or lower than 1.29 mmol/l for 
women.
f) Metabolic syndrome was assessed using the International Diabetes Federations (IDF) criteria [IDF 2005] and defined as having waistline of 94 cm or more 
for men or 80 cm or more for women and at least two of the following components: the serum triglycerides level 1.7 mmol/l or higher, the serum high-
density lipoprotein cholesterol level lower than 1.02 mmol/l for men or lower than 1.29 mmol/l for women, high blood pressure in terms of systolic pressure 
130 mmHg or more or diastolic pressure 85 mmHg or more or treatment for previously diagnosed hypertension and raised fasting plasma glucose level 5.6 
mmol/l or higher, or previously diagnosed type 2 diabetes.Journal of Circadian Rhythms 2009, 7:5 http://www.jcircadianrhythms.com/content/7/1/5
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circadian gene expression [36]. It remains to be elucidated
whether PER proteins are independently important for
glucose homeostasis or does their role in the circadian
clock lead to the effects seen.
Woon et al. found association between Arntl and hyper-
tension and type 2 diabetes mellitus [29]. Our SNP selec-
tion did not include the SNPs used in their study, which
can explain why we failed to see any associations. Recent
studies have also found association between Clock-gene
polymorphism and the metabolic syndrome in man
[13,14]. It is of note that we did not find support to these
links in our study. We did, however, find several interest-
ing associations, which failed to show statistically signifi-
cant p-values after correction (Table 3). These include
associations between DRD2  rs6277 and blood glucose
levels,  PLCB4  rs6077510 and Per2  SNP rs934945 and
waist circumference, and Vipr2 rs885863 and low HDL
cholesterol level. In addition, Per2  SNP rs934945 was
associated with the metabolic syndrome.
There are some limitations in our study. We relied on a
self-report questionnaire when assessing the seasonal var-
iations in mood and behavior. However, this question-
naire has been reported to have high sensitivity and
specificity [37] and can be regarded as valid for the life-
time-retrospective assessment of routine seasonal varia-
tions in mood and behavior.
Our study bears several strengths. This was a population-
based and nation-wide study. Its sample size was rela-
tively big and representative of the general population
aged over 30 living in a northern European country, Fin-
land. Hence, these data can be generalized directly to con-
cern the whole adult population of Finland, or any
population having similar living conditions. We had rich
phenotype data with reliable laboratory tests and valid
assessments of syndromes on our focus. The single-nucle-
otide polymorphisms used were selected for their poten-
tial role in the function of the gene, which augments the
possibility that the genotype seen here contributes to the
phenotype although experimental analysis is needed for
verification.
Conclusion
Our findings herein link the circadian gene variants and
risk factors of the metabolic syndrome. Npas2 was associ-
ated with hypertension and Per2 with blood glucose lev-
els. Our findings give support to the view that there are
relevant relationships between circadian clocks and meta-
bolic syndrome.
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